Abstract-Cardiometabolic and vascular disease, with their associated secondary complications, are the leading cause of morbidity and mortality in Western society. Chronic inflammation is a common theme that underlies initiation and progression of cardiovascular disease. In this regard, monocytes/macrophages are key players in the development of a chronic inflammatory state. Over the past decade, epigenetic modifications, such as DNA methylation and posttranslational histone processing, have emerged as important regulators of immune cell phenotypes. Accumulating studies reveal the importance of epigenetic enzymes in the dynamic regulation of key signaling pathways that alter monocyte/macrophage phenotypes in response to environmental stimuli. In this review, we highlight the current paradigms of monocyte/ macrophage polarization and the emerging role of epigenetic modification in the regulation of monocyte/macrophage phenotype in obesity, diabetes mellitus, atherosclerosis, and abdominal aortic aneurysms.
C ardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide and currently affects ≈50% of the US population. 1, 2 Further, CVD inflicts a major socioeconomic burden with both direct and indirect costs exceeding $1.1 trillion. 2 The main causes of CVD include obesity, diabetes mellitus, hypertension, hyperlipemia, and atherosclerosis. Although these conditions are diverse, chronic inflammation with monocyte/macrophage infiltration plays a central role and represents a pathological hallmark of disease development. [3] [4] [5] For example, within atherosclerotic plaques, macrophages represent major contributors to the inflammatory response through their secretion of proinflammatory mediators and their eventual death by necrosis or apoptosis. 4 Dying macrophages release their lipid contents and tissue factors, which leads to the formation of a prothrombotic necrotic core, a key component of unstable plaque. Likewise, within diabetes mellitus, wound healing is altered because of chronic macrophage-mediated inflammation with excessive inflammatory cytokine production and an associated failure of tissue macrophages to transition to an anti-inflammatory phenotype. 6, 7 Finally, in obesity, the infiltration of monocytes into adipose tissue results in increased inflammatory cytokine production, particularly TNF-α (tumor necrosis factor), MCP-1 (monocyte chemotactic protein), and iNOS (inducible NO synthase). 8 Several human and murine studies have demonstrated that the severity of adipose tissue macrophage (ATM) inflammation correlates with insulin resistance. [9] [10] [11] [12] Please see https://www.ahajournals.org/atvb/atvbfocus for all articles published in this series.
Macrophages are characterized by a remarkable degree of plasticity and are able to rapidly adapt to a wide range of environmental cues. 13 The classical view presents a highly simplified M1/M2 phenotype dichotomy, based on in vitro experiments, where M1, or classically activated, macrophages are induced by proinflammatory mediators such as lipopolysaccharide and IFN-γ (interferon) and secrete proinflammatory cytokines including IL-6 (interleukin), IL-1β, iNOS, and TNF-α. In contrast, M2, or alternatively activated, macrophages play a role in tissue repair, angiogenesis, and resolution of inflammation. These macrophages are induced by the anti-inflammatory mediators, IL-4 and IL-13, and secrete high levels of anti-inflammatory IL-10. Disease pathology is frequently associated with dynamic changes in macrophage phenotype, with classically activated M1 cells implicated in initiating and sustaining inflammation and M2 cells associated with resolution. 14 An increasing number of studies have demonstrated the importance of epigenetics in the regulation of macrophage phenotype. 15, 16 Epigenetic modifications can be influenced by micro-and macroenvironmental factors which have been shown to induce cell-specific changes to the epigenetic landscape. 17 As such, CVDs elicit epigenetic changes that alter gene expression and hence, cell function, in a variety of cell types, including monocytes/macrophages. 18, 19 Over the past decade, substantial work has been conducted on the mechanisms of epigenetic regulation of macrophage activation. Through characterization of human tissue samples and animal models, a complex picture of cellular processes has been shown to play pivotal roles in monocyte/macrophage inflammation in CVD. In this brief review, we will discuss recent findings that provide mechanistic insight into the role of epigenetics in the regulation of macrophage phenotype and function in the setting of inflammation. Additionally, we will highlight the impact of epigenetic modifications on maladaptive inflammation in cardiometabolic and vascular disease. ++ and survey the vasculature while being involved with early responses to inflammation and tissue repair. 23 Despite the importance of circulating blood monocytes in CVD, at the local tissue level macrophages influence inflammation and homeostasis. In-depth lineage tracking studies have demonstrated subsets of tissue macrophages are derived from multiple sources. Recent investigations have shown that tissue-resident macrophages can originate from embryonic progenitor cells that migrate into the tissues during embryonic and fetal life and are self-maintained during adulthood. 21, 24 This embryonic origin and steady-state self-maintenance applies to cardiac-and vascular-resident macrophages as local proliferation of tissue macrophages are involved in several cardiovascular processes. 25, 26 However, during periods of inflammation or injury, circulating monocytes originating from the bone marrow and extravasating into tissues serve as the primary external source of monocyte-derived macrophages. 27 Macrophages are an essential component of innate immunity and play a central role in inflammation and host defense.
Monocyte/Macrophage Plasticity
14 Moreover, these cells fulfill homeostatic functions beyond defense, including the regulation of metabolism and hematopoiesis. As such, macrophages maintain a high degree of functional flexibility to effectively respond to the diverse array of agents they may encounter. The classic view presents macrophage phenotypes based on their in vitro characterization with a particular focus on the dichotomy between classically activated M1 macrophages and alternatively activated M2 macrophages. 28 TNF, and IL-12) and inflammatory chemokines, including chemokine CXCL1 (C-X-C motif ligand 1) and CXCL2 and CCL2-5 (chemokine C-C motif ligand 2-5). Classical activated macrophages also produce reactive oxygen and nitrogen intermediates, the latter by iNOS. 29 In contrast, M2 macrophages are induced by IL-4/IL-13 and core genes expressed by M2 macrophages include scavenger receptors, growth factors (HB-EGF [heparin-binding epidermal growth factor] and IGF [insulin-like growth factor]), and suppressors of inflammation and immunity such as IL-10. 30 Despite the classification of macrophage subsets being well-defined in vitro, distinction of macrophage subsets in vivo is less clear as cells simultaneously express M1 and M2 markers. Indeed, the simplified M1/ M2 outlook ignores the innumerable variety of macrophage subsets in vivo corresponding to a spectrum of activation and is characterized by a combination of markers. As such this has been replaced with a continuum of macrophage activation states, thus taking into account the diversity of the macrophage in tissues.
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Epigenetic Modifications
Epigenetics refers to developmentally or environmentally induced modifications that do not alter the genetic code but instead control how information encoded in DNA is expressed in a tissue-and context-specific manner. Epigenetic marks have traditionally been considered to be stable, potentially transmissible to progeny, and to underlie stable differentiation into various cell types that express markedly different patterns of gene expression. Recently, it has become clear that epigenetic chromatin marks are dynamically regulated in response to environmental cues. This has resulted in a shift in the usage of epigenetics to include transient changes in chromatin in response to external stimuli that control gene expression. 31 Overall, epigenetic changes can be classified into 3 main categories: (1) DNA methylation; (2) posttranslational histone modifications; and (3) noncoding RNA. The latter does not create heritable changes but is often grouped with epigenetic mechanisms because of its important regulatory role involving nonprotein-coding regions of the genome. About DNA methylation, it is predominantly associated with transcriptional repression and is characterized by transfer of a methyl group to the cytosine ring of DNA by DNA methyltransferases (DNMTs) to form 5-methylcytosine. 32 DNMT-3A and DNMT-3B deposit de novo methylation marks, whereas DNMT-1 is responsible for maintaining these marks because these marks must be reestablished with each cell division. 33 In mammals, the vast majority of DNA methylation in somatic cells occurs at clusters of CpG dinucleotides termed CpG islands, and ≈40% of genes contain these islands in their promoters. 34 In eukaryotes, DNA is packaged into repeating units called nucleosomes by wrapping around multimeric histone proteins. When nucleosomes are organized into tightly packed bundles (heterochromatin), transcription is inhibited by barring access of transcriptional machinery. Conversely, when chromatin is relaxed (euchromatin), the nucleosomes resemble beads on a string and this state is associated with active transcription. Each histone (H) protein is an octamer comprised of 2 sets of H2A, H2B, H3, and H4 proteins with a single histone H1 linker protein between nucleosomes. Each histone subunit has an N-terminal tail containing a lysine (K) residue that protrudes away from the surface of the histone octamer creating an exposed surface. Here, histone modifying enzymes can regulate macrophage phenotype through the addition or removal of acetyl or methyl groups. 16 First, acetylation and deacetylation are facilitated by histone acetyltransferases and histone deacetylases (HDACs), respectively. Histone acetylation is linked to transcriptional activity, whereas histone deacetylation is associated with transcriptional repression. 35 Bromodomain and extraterminal proteins recognize histone acetylation marks and initiate the assembly of the transcriptional machinery. 36 Similarly, methylation and demethylation of histones are achieved by histone methyltransferases and histone demethylases, respectively. 16 Histone methylation can induce both transcriptional activation and repression, depending on the number and location of the methyl groups. An active transcriptional state is characterized by positive marks such as di-or trimethylation (me2/me3) at H3K4, H3K36, and H3K79. A repressed transcriptional state manifests itself by increased markings at H3K9me2/me3 and H3K27me3. 37 Last, noncoding RNAs-including microRNAs (miRs) and long noncoding RNAs (lncRNAs)-do not directly affect chromatin architecture but play an essential role in posttranscriptional regulation of gene expression. lncRNAs are a large group of nonprotein-coding transcripts, which are >200 nucleotides in length. Although the mechanisms by which lncRNAs regulate gene expression are still incomplete, emerging evidence has suggested that lncRNAs can control gene expression at multiple levels including epigenetic control, transcription, RNA processing, and translation. Many lncRNAs have been found to be significantly enriched in the chromatin fraction, and a common function of these lncRNAs is to recruit chromatin modifying complexes, including the PcG (polycomb group) or TrxG (trithorax group), to create a repressive chromatin state or an active chromatin state as well as affect gene expression either in cis or in trans to distant target genes. 38 Alternatively, some lncRNAs can form RNA-protein complexes with transcription factors and influence the localization and activity of the transcription factors that they bind, subsequently regulating gene expression. 39, 40 About miRs, these are evolutionary conserved, small noncoding single-stranded RNAs that are produced by multistep processes of transcription, nuclear export and cytoplasmic cleavage, and work primarily as posttranscriptional repressors via targeting the 3′-untranslated region of mRNA to provoke its degradation or its translational repression. 41 It is estimated that >60% of all protein-coding genes are directly regulated by miRs. 42 Furthermore, a given miR may bind to and regulate >1 target, sometimes as a part of the same signaling pathway, adding multiple levels of regulation. As such, miRs are fine-tuners of gene expression patterns in response to pathophysiological stimuli. phenotype 15, 37, 43, 44 and are summarized in Figure 1 . Briefly, DNA methylation, histone methylation, and histone acetylation have been shown to influence macrophage phenotype and inflammatory gene production. One representative enzyme involved in histone methylation is SMYD (SET and MYN domain)-3, an H3K4 methyltransferase, which has been shown to positively regulate M2 polarization. Its expression levels increase in human monocyte-derived macrophages with exposure to the combination of M-CSF (macrophage colony stimulating factor), IL-4, and IL-13 and decrease with exposure to M1 stimulation. 44 Upregulation of SMYD-3 coincides with methylation and transcriptional activation of ALOX-15 (15 lipoxygenase), a lipoxygenase M2 marker. Another epigenetic enzyme which has been shown to regulate macrophage phenotype in multiple studies is Jmjd (Jumonji domain-containing protein)-3, an H3K27 demethylase. Jmjd-3 has also been recognized as an essential regulator of M2 polarization through its induction of Irf-4 (interferon regulatory factor 4), Arg-1 (arginase), CD206, and other M2 markers in IL-4-stimulated and IL-4+IL-13-stimulated mouse bone marrow-derived macrophages. 45 However, recent study by Yan et al 46 demonstrated that proinflammatory cytokine induction by the acute-phase protein serum amyloid A also depends on Jmjd-3 expression. 47 Further, targeting Jmjd-3 with small molecule inhibitors impairs inflammatory responses in human primary macrophages. 48 Overall, Jmjd-3 is required for various responses to different external stimuli including IL-4, RANKL (receptor activator of nuclear factor kappa-Β ligand), M-CSF, SAA (serum amyloid A), and lipopolysaccharide, but is not associated with a single macrophage polarization state likely reflecting the need for Jmjd-3 to enable responses to various environmental stimuli.
Regarding histone acetylation, H3 acetylation is an important regulator of macrophage phenotypic expression. 49 Although current investigations into the importance of histone acetyltransferases in the acetylation of H3 are lacking, extensive observations have been made concerning the role of HDAC-3. HDAC-3 blocks NF-κB signaling by deacetylation of the NF-κB p65 subunit and allowing its association with the IκB-α. 50 ,51 HDAC-3 is a key regulator of M1 macrophage polarization and in parallel acts as a brake for M2 macrophage polarization. HDAC-3 also is an important player in the lipopolysaccharide-induced expression of about half of the M1 macrophages-associated inflammatory genes. 52 Similarly, HDAC-5 is the central regulator of the inflammatory response of macrophages.
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Epigenetic Regulation Targeting Monocytes/ Macrophages in CVD
Over the past decade, multiple investigations have demonstrated that chronic inflammation often underlies the pathogenesis of cardiometabolic and vascular disease. Inflammatory responses, based on macrophage polarization, depend on the cell's ability to respond to environmental changes and stimuli. Given the impact of epigenetic modifications on the dynamic regulation of macrophage phenotype, recent studies have examined the role of epigenetics in disease progression. This section will focus on the role of epigenetic modifications regulating macrophage phenotype in the pathogenesis of obesity, diabetic wound healing, atherosclerosis, and aortic aneurysms.
Obesity/Metabolic Syndrome
Obesity-associated insulin resistance, diabetes mellitus, and metabolic syndrome are sustained by chronic subclinical inflammation. 5 In obese subjects and mice, adipocytes release mediators such as MCP-1, TNF, or free fatty acids, which promote the recruitment and activation of ATMs. 54 In turn, ATMs produce inflammatory cytokines (eg, TNF, IL-6, and IL-1β) that counteract the insulin-sensitizing action of adiponectin and leptin, leading to insulin resistance. 55 ATMs from obese mice and humans are polarized toward an M1 phenotype, with upregulation of TNF-α and iNOS. In contrast, lean ATMs express high levels of M2 genes, including IL-10, Ym-1, and Arg-1. 56 Interestingly, weight loss is associated with a shift back to an M2 phenotype. Progress has been made in defining the molecular pathways that account for polarization of ATMs in obesity. 57 Multiple investigations have supported the notion that epigenetics significantly impact inflammatory macrophages in patients with obesity and diabetes mellitus. Increased levels of saturated fatty acids lead to upregulation of DNMT-3b in macrophages, thus fostering M1 polarization and adipose tissue inflammation. Targeting DNMT-3b decreased inflammation and restored insulin sensitivity in adipocytes. Along the same line, inhibition of DNA methylation by myeloid deletion of DNMT-1 prevented obesity-induced macrophage polarization, inflammation, and insulin resistance by epigenetic regulation of the PPAR-γ1 (peroxisome proliferator-activated nuclear receptor) promoter. 58 Recently, lncRNAs have been proposed to have a regulatory role for macrophage polarization in cardiometabolic disease as M1-and M2-polarized macrophages present with distinct lncRNA profiles. 59 Two lncRNAs shown to play a role in macrophage polarization in human and murine diabetic macrophages are E330013P06 and Dnm3os. Overexpression of E330013P06 lncRNA in macrophages-induced inflammatory gene expression, enhanced responsiveness to inflammatory signals, and increased foam cell formation. 19 Separately, expression of Dnm3os is upregulated in macrophages and monocytes under diabetic conditions via NF-κB activation. Diabetic macrophage overexpression of Dnm3os altered global histone modifications, upregulated inflammatory gene expression and phagocytosis. 60 Histone-specific modification has also been shown to have a role in modulating macrophage phenotype in cardiometabolic disease. Specifically, hyperglycemia decreased the inhibitory H3K9me3 mark on inflammatory genes, IL-6, IL-12, and MIP-1α (macrophage inflammatory protein) in human monocytes. Likewise, murine diabetic models noted increased activating H3K4 methylation marks at the promoter of the inflammatory NF-κB p65 subunit, mediated by the histone methyltransferases SETD-7 (SET domain containing lysine methyltransferase) and SETD-9 resulting in increased expression of NF-kB-dependent genes VCAM-1 (vascular cell adhesion molecule), ICAM-1 (intercellular adhesion molecule), and MCP-1. 61 Furthermore silencing of SETD-7/9 by small hairpin RNAs attenuated inflammatory gene expression elicited by advanced glycation end products seen in chronic diabetes mellitus. 61 Last, acetylation has also been shown to impact macrophage phenotype in cardiometabolic syndrome as acetylation of H3 at the promoter of TNF-α and COX-2 genes was enhanced in monocytes isolated from diabetic subjects. Moreover, the H3 deacetylase SIRT (sirtulin)-1 is downregulated in the adipose tissue of obese individuals, leading to enhanced macrophage recruitment via increased chemoattractant and cytokine production. 62 
Wound Healing
Impaired wound healing is a major secondary complication of type 2 diabetes mellitus that often results in limb loss and disability. Normal tissue repair progresses through discrete phases including hemostasis, inflammation, proliferation, and remodeling. In diabetes mellitus, progression through these phases is impaired resulting in a sustained inflammatory state and dysfunctional epithelialization in the wound. Monocytes are recruited to the wound site very early, during the inflammatory phase, where they differentiate into macrophages and dendritic cells. There is substantial evidence that infiltrating monocytes/macrophages are critical for establishing the initial inflammatory phase as well as promoting the transition from a proinflammatory to anti-inflammatory environment. 63 In diabetic wounds, this transition does not occur and macrophages remain in a persistent inflammatory state. Our group recently reported that Ly6C hi monocytes/macrophages, which have been shown to promote inflammation, normally transition to Ly6C lo ; however, in diabetic wounds, a second wave of Ly6C hi macrophages are recruited to the wound during the reparative phase and fail to transition to the anti-inflammatory Ly6C lo cells contributing to a sustained proinflammatory environment. 64 Several studies have shown a role for macrophage epigenetic modification in type 2 diabetes mellitus and diabetic wounds 65 ( Figure 2 ). Investigations using both genetic (db/db) and diet-induced obesity murine models of diabetes mellitus, showed that DNA methylation with DNMT-1 or DNMT-3b was elevated in bone marrow-derived macrophages and promoted a proinflammatory macrophage phenotype. Moreover, DNMT-1 or DNMT-3b knockdown improved wound healing in db/db mice and decreased inflammation. 46 Separately, histone methylation impacts macrophage phenotype in diabetic wounds. Our laboratory and others have shown that expression of Jmjd-3, the histone demethylase targeting H3K27me3, is increased in wound macrophages in a diet-induced obesity mouse model of diabetes mellitus. 66, 67 Increased JMJD-3 releases the repressive H3K27me3 mark thereby promoting expression of IL-12 in wound macrophages, and this phenomenon can be reversed by JMJD-3 inhibition. 66 Similarly, a report by De Santa et al 67 showed that Jmjd-3 expression was increased in macrophages in response to inflammatory stimuli and was responsible for regulating during bone marrow differentiation. Another histone methyltransferase involved in diabetic wound healing is MLL-1 (mixed-lineage leukemia) with site specificity for H3K4. CD14 + monocytes isolated from type 2 diabetic patients and wound macrophages isolated for diet-induced obesity murine model displayed increased MLL-1, increased H3K4me3 at inflammatory gene promoters, and increased inflammatory mediator production compared with controls. The use of an MLL-1 inhibitor or myeloid-specific MLL-1 knockout (Mll1 f/f Lyz2 Cre+ ) resulted in decreased inflammatory cytokine transcription and improved wound healing. 68 Another critical aspect of diabetic tissue repair is angiogenesis. Recent publications have demonstrated that following tissue ischemia, diabetic mice exhibited impaired angiogenesis and arteriogenesis. This was associated with promoter hypomethylation of multiple inflammatory genes in tissue macrophages modify macrophage phenotype toward a proinflammatory M1 as opposed to anti-inflammatory, proangiogenic M2 phenotype. 69 Last, it has recently been demonstrated that hyperglycemia leads to changes in the miR signature in wound healing which plays a role in the dysregulated inflammation of diabetic wounds. 70 For example, miR-125b epigenetically enhances macrophage activation by increasing the responsiveness to IFN-γ and concurrently inhibits the reparative phenotype by targeting the M2 transcription factor IRF-4.
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Atherosclerosis
One of the earliest pathogenic events in atherosclerosis is the recruitment of circulating monocytes to the artery wall in areas of endothelial dysfunction and lipoprotein retention. On differentiation into macrophages, these cells play central roles in the pathophysiology of atherosclerosis by maintaining lipid homeostasis in the vessel wall and secreting inflammatory mediators. Lipoprotein uptake by macrophages in the nascent plaque results in the formation of lipid-laden macrophage foam cells that are hallmarks of atherosclerosis. 4 These foam cells persist in the artery wall, setting off a maladaptive immune response that mediate the recruitment and activation of other immune cells, thereby chronically sustaining the inflammation that fuels plaque progression. Macrophage cholesterol homeostasis is maintained by the balance between cholesterol uptake, endogenous synthesis, and efflux. Modifications to histones, both methylation and acetylation, have been shown to play a role in macrophage cholesterol metabolism ( Figure 3A) . Recently, the histone methyltransferase EZH (enhancer of zeste homolog)-2, which trimethylates H3K27, was shown to exacerbate atherosclerosis in a murine model by inhibiting macrophage cholesterol efflux via ABCA-1 (ATP-binding cassette transporter) thereby promoting foam cell formation. 72 In contrast, alterations by HDACs, including SIRT-1 and SIRT-6, increase cholesterol efflux by the activation of ABCA-1 and ABCG-1 (ATP-binding cassette subfamily G member) resulting in a reduction in macrophagederived foam cell formation and its associated inflammation. 15 Beyond cholesterol homeostasis, histone modifications also influence macrophage phenotype within the atherosclerotic plaque as alterations in the levels of methylation and acetylation have been observed on H3K9 and H3K27 in macrophages from human advanced atherosclerotic plaques, compared with healthy controls. 73 Using a high-throughput RNA-sequencing approach, Neele et al 74 demonstrated that absence of JMJD-3, an H3K27 demethylase, resulted in exacerbation of atherosclerotic plaque morphology and decreased expression of gene sets responsible for M2 macrophages polarization. Further, the expression of several HDACs, HDAC-3 and HDAC-9, are induced on monocyte differentiation to macrophages in LDLr −/− mice fed an atherogenic diet. Systemic deletion or myeloid-specific deletion of HDAC-9 and HDAC-3, respectively, attenuated atherosclerosis by an increase in M2 macrophage polarization and reduction in proinflammatory gene expression. 52 Separately, recent genomewide association studies revealed that a genetic variant in the loci corresponding to HDAC-9 is associated with coronary artery and atherosclerotic disease. 75 ,76 HDAC-9 has been shown to play a vital role in cholesterol homeostasis and inflammation as systemic and bone marrow cell deletion of HDAC-9 resulted in upregulation of lipid homeostatic genes, downregulation of inflammatory genes, and polarization toward an M2 phenotype via increased accumulation of total acetylated H3 and H3K9 at the promoters of ABCA-1 and ABCG-1 in macrophages. 77, 78 One of the most important prognostic factor for atherosclerotic CVD is age, and the accumulation of genomic DNA mutations is a well-known feature of cellular aging. Recently, it has been demonstrated that somatic mutations leading to clonal expansion in the absence of other hematologic abnormalities, or clonal hematopoiesis of indeterminate potential predisposed to increase risk of atherosclerotic CVD. A pioneering study demonstrated that somatic mutations in DNMT-3A, TET-2, ASXL-1, and JAK-2 were each individually associated with coronary heart disease. 79 Supporting a major role of mutations in the DNMT, DNMT-3A, in clonal hematopoiesis in humans, mouse HSPCs exhibiting heterozygotic DNMT-3A loss of function develop a competitive advantage and myeloid skewing over time. 80 Importantly, DNMT-3A deficiency has also been reported to lead to several potentially proatherogenic phenotypes in immune cells, including exacerbated proinflammatory activation of mast cells, and restrained immunosuppressive function in myeloid-derived suppressor cells. 81 However, DNMT-3A inhibition has also been shown to limit the production of type I IFNs in macrophages, which could potentially protective. 82 Therefore, given the complexity of the immunomodulatory functions of DNMT-3A, carefully designed experimental studies will be required to determine the potential contribution of somatic mutations in this gene to CVD.
Alterations in miRs have also been implicated in aberrant macrophage cholesterol homeostasis and polarization during atherosclerosis. Many miRs have been implicated in macrophage cholesterol metabolism and have been previously described in detail [83] [84] [85] and summarized in Figure 3B . To briefly review, miR-125a-5p and miR-146 decrease lipid uptake and cytokine release in oxidized LDL (low-density lipoprotein)-stimulated macrophages, in part, by targeting the genes oxysterol-binding protein-like-9 and TLR-4, respectively.
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Figure 3. Histone modifications, microRNAs (miRs), and long noncoding RNAs (lncRNAs) implicated in atherosclerosis. A, Histone modifying enzymes regulate the polarization of macrophages toward classical M1 or alternative M2 inflammatory activation. Within atherosclerosis, specifically, studies have shown the histone methyltransferase, EZH-2 (enhancer of zeste homolog), and the histone acetyltransferase, p300, polarize macrophages toward an M1 phenotype. In contrast, the histone demethylase, JMJD-3 (Jumonji domain-containing protein), polarizes toward an M2 phenotype. In addition, histone-modifying enzymes can have stimulatory (green arrow) or inhibitory (red arrow) effects on ABCA-1/ABCG-1 (ATP-binding cassette transporter/ATP-binding cassette subfamily G member) altering cholesterol efflux and reverse cholesterol transport. B, The initial stages of atherosclerosis include adhesion of blood monocytes to the activated endothelium, their maturation into macrophages and their activation and uptake of ox-LDL (oxidized low-density lipoprotein) to form macrophagederived foam cells. Cholesterol efflux mechanisms, aided by ABCA-1/ABCG-1 and other factors, help to regress lesion development. miRs and lncRNAs exhibit diverse roles in atherosclerotic progression through the involvement of macrophage activation, foam cell formation, and cholesterol efflux. Representative miRs and lncRNAs that stimulate these processes are shown in yellow boxes. The miRs and lncRNAs highlighted in red boxes have been shown to inhibit macrophage activation, foam cell formation, or cholesterol efflux. HDAC indicates histone deacetylase; HDL, high-density lipoprotein; and SIRT, sirtulin.
Furthermore, numerous miRNAs have been identified that inhibit macrophage cholesterol efflux via ABCA-1 thereby promoting foam cell formation, including miR-26, miR-33, miR-106, miR-128-1, miR-130b, miR-144, and miR-148, and miR-302a. 83 Beyond cholesterol homeostasis, miRs also influence macrophage phenotype during progression of atherosclerosis as in response to microenvironmental signals, macrophages can initiate different activation programs, including the classical proinflammatory and anti-inflammatory phenotype. One miR involved in regulation of macrophage phenotype is miR-33, which regulates macrophage cellular metabolism to alter the cell's inflammatory phenotype. miR-33 reduces fatty acid oxidation, the metabolic program that fuels M2 macrophages, and promotes aerobic glycolysis, which in turn sustains the inflammatory M1-macrophage phenotype. 87 Inhibition of miR-33 metabolically reprograms plaque macrophages to the M2 phenotype involved in resolving inflammation and tissue repair. Further, miR-155 and miR-342-5p can also reprogram macrophages from the M2 to M1 phenotype, thereby impacting accumulation of M1 macrophages. 88, 89 miR-155 expression is significantly higher in CD14 + monocytes from patients with coronary artery disease than from healthy controls and is induced by oxidized forms of LDL in macrophages. miR-155 acts to repress negative regulators of inflammatory cytokine signaling, such as SOCS, and thereby promoting the release of proinflammatory cytokines. 90 However, miR-146a exerts atheroprotective effects on macrophages by inhibiting the activation and secretion of proinflammatory cytokines via suppressing NF-κB. 91 Notably, expression of miR-146a in hematopoietic cells is crucial in restraining the chronic inflammatory response in vivo. 92 miR27a can promote markers of anti-inflammatory macrophages and secretion of IL-10. 93 Last, recent literature has demonstrated an interesting interaction between miRs and histone modifying enzymes with miRs regulating the expression of epigenetic enzymes. 94, 95 The histone methylase, EZH-2, has been shown to be regulated by expression of miR-26a, miR-101, miR-205, and miR-21 in a variety of disease states. [96] [97] [98] [99] Further, members of the miR-29 and miR-148 family directly target DNMTs 3A and 3B in nonsmall cell lung cancer cells and acute myeloid leukemia. [100] [101] [102] Thus, miRs may be involved in the establishment and maintenance of DNA methylation. At this time it is undefined if miRs have similar roles regulating expression of epigenetic enzymes in macrophages, but it is hypothesized that parallel miR and epigenetic enzyme interactions exist in innate immune cells during atherosclerotic development.
Several studies have shown important contributions of lncRNAs in atherosclerosis and have been recently summarized. 103 In addition, accumulating evidence suggests that lncRNAs guide chromatin-modifying enzymes to specific loci contributing to the epigenetic regulation of many autosomal genes. 104, 105 About macrophages specifically, lncRNAs are key drivers of sterol regulation during atherogenesis. RP5-833A20.1 is an intronic lncRNA that regulates the transcription factor NFIA (nuclear factor I A) in human foam cell macrophages by modulating the miR, hsa-miR-382-5p. 106 Further, recent study has identified the lncRNA, MeXis, which influences chromatin architecture at the locus of ABCA-1 resulting in enhanced ABCA-1 expression. 107 This effect is dependent on the transcriptional coactivator DDX-17. Genetic deletion of MeXis from immune cells in a murine model markedly enhances foam cell formation and accelerates atherosclerosis. In addition, perturbing the human orthologue of MeXis influences ABCA-1 levels and human macrophage function. Finally, it has been noted that HOXC-AS1 (HOXC cluster antisense RNA 1) is downregulated in atherosclerotic plaques and that overexpression of HOXC-AS1 reduces ox-LDL (oxidized LDL)-induced cholesterol accumulation in macrophages by activating HOXC-6 (homeobox C).
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Abdominal Aortic Aneurysm
Abdominal aortic aneurysms (AAAs) are a degenerative CVD resulting in the progressive dilation of the aorta that may lead to rupture which if occurs is fatal in 80% of cases. This disease represents a global health concern as AAAs are responsible for between 2% and 4% of deaths in white males over the age of 65. 109 Currently, surgical repair is the only therapeutic option to treat AAA rupture with a lack of proven medical therapy to prevent AAA progression. The exact etiological basis of AAA is still not fully understood; however, macrophage inflammation represents a pathological hallmark of disease development with the majority of macrophages within the aortic wall originate from circulating monocytes. 110, 111 At this time, the contribution of tissue-resident macrophages remains poorly defined. Recently, through the characterization of surgical samples and animal models investigations have demonstrated a role of epigenetic modification in monocytes/ macrophages within the pathogenesis of aortic aneurysm formation. Global methylation levels within peripheral blood mononuclear cells are significantly altered on CpG islands in AAA patients in comparison to controls and exhibit a positive correlation with increased aortic diameter. 112 Further within human AAA samples, expression of HDACs, specifically class I and IIa, were found to be increased in comparison to control samples and colocalized with macrophages within the aortic wall. Using murine models, treatment with HDAC class I (MS-275) or class IIa (MC-1568) inhibitors reduced AAA incidence, decreased macrophage inflammation, and reduce proinflammatory mediators. 113 Last, miRs have also been shown to regulate macrophage function in murine models of AAAs as miR-33 deficiency resulted in decreased M1-gene expression, protease activity, and macrophage infiltration into the aortic wall. Further, bone marrow transplant of miR-33 deficient cells decreased AAA formation suggesting myeloid-specific miR-33 may be instrumental in AAA pathogenesis. 114 Although additional research is necessary to further uncover the role of epigenetic regulation of macrophage phenotype in AAA pathogenesis, given the impact of epigenetic modification in other CVDs this represents a promising field of discovery.
Conclusions
During the past several decades, significant progress has been achieved in the understanding and treatment of cardiometabolic and vascular disease. However, the persistent clinical impact of these conditions suggests more work remains to be done. To improve treatment of cardiovascular patients, targeting inflammatory pathways offers additional benefits over and in combination with traditional therapies. 115 Evidence discussed here suggests that epigenetic processing plays a central role in the balance of macrophage phenotypes as well as the regulation of inflammation during the pathogenesis of cardiometabolic and vascular disorders. Inflammatory responses and macrophage polarization depend on the cell's ability to respond to environmental changes and stimuli. Epigenetic mechanisms allow such adaptive responses and enhance macrophage diversity and plasticity. However, maladaptive epigenetic changes contribute to the persistence of disease inflammation. Therefore, pharmacological intervention to reprogram a diseased epigenetic landscape is an attractive therapeutic target for the treatment of cardiovascular disorders. The understanding of chromatin architecture has led to the design of specific molecules to modulate chromatin accessibility by enhancing or repressing epigenetic marks on DNA/histone complexes. 116 New small molecules that reduce the polarization and activation of inflammatory cells and in particular macrophages at inflammatory sites are considered to be the next generation of anti-inflammatory drugs. Noteworthy, some of these drugs have been already approved for the treatment of several conditions including cancer. The challenge for future investigations is how to achieve tissue-specific modulation of chromatin in monocytes/macrophages because systemic inhibition or activation may lead to adverse side effects. With future research, epigenetics will serve as a useful framework through which to gain new insights into the role of myeloid cells in cardiometabolic and vascular disease.
